Key Takeaways
- • Qiagen and EQT XI announced an agreement under which Crown NL Bidco B.V., indirectly controlled by EQT XI, will launch an all-cash voluntary public takeover offer for all outstanding Qiagen shares, valuing the company at approximately $12.1 billion including about $1.1 billion of net debt.
- • The offer represents a 40.3% premium to the XETRA closing price of $37.21 on 8 July 2026 and a 46.9% premium to the three-month VWAP of $35.53, per the BioXconomy report.
- • Abu Dhabi Investment Authority subsidiary Luxinva S.A. and CPP Investment Board Europe Inc. are co-investors in the bidder structure.
- • The Qiagen boards unanimously back the transaction; implementation of post-closing measures requires at least 80% shareholder approval of votes cast, though boards may proceed with substantial majority support.
- • Closing is currently expected in mid-2027.
Summary
Qiagen and the EQT XI fund have agreed terms under which Crown NL Bidco B.V., a holding company indirectly controlled by EQT XI, will launch an all-cash voluntary public takeover offer for all outstanding Qiagen shares, according to BioXconomy. EQT Private Equity is managed by affiliates of EQT AB, headquartered in Stockholm, Sweden. The bidder structure also includes indirect participation from co-investors Luxinva S.A., a subsidiary of the Abu Dhabi Investment Authority, and CPP Investment Board Europe Inc., a subsidiary of the Canada Pension Plan Investment Board.
The offer carries a 40.3% premium to the XETRA closing price of $37.21 recorded on 8 July 2026, the last trading day before market reports surfaced regarding private equity interest in the company. Measured against the three-month volume-weighted average price of $35.53 up to that date, the premium rises to 46.9%. In total, the transaction values Qiagen at approximately $12.1 billion at current exchange rates, including around $1.1 billion of net debt.
A Qiagen spokesperson said EQT shares the company's strategic priorities and brings sector experience in healthcare and life sciences, a global network and operational capabilities. The spokesperson said EQT has agreed to support Qiagen's long-term development, including commitments relating to strategy, business, key brands, operational footprint, R&D, employee arrangements, prudent financing and culture. The Qiagen boards concluded unanimously that private ownership under EQT offers the best foundation for the company's next phase of growth, combining operational flexibility with what they describe as certain and attractive value for shareholders.
Implementation of the post-closing measures will proceed if shareholder approval reaches at least 80% of votes cast. The boards retain discretion to proceed below that threshold if they determine it serves the best interests of the company and its stakeholders, provided there is support from a substantial majority of the shareholder base. Closing of the takeover offer is currently expected in mid-2027.
The transaction revives private interest in Qiagen after Thermo Fisher Scientific announced in March 2020 that it would acquire the company for $11.5 billion; that deal lapsed in August 2020.
The offer carries a 40.3% premium to the XETRA closing price of $37.21 recorded on 8 July 2026, the last trading day before market reports surfaced regarding private equity interest in the company. Measured against the three-month volume-weighted average price of $35.53 up to that date, the premium rises to 46.9%. In total, the transaction values Qiagen at approximately $12.1 billion at current exchange rates, including around $1.1 billion of net debt.
A Qiagen spokesperson said EQT shares the company's strategic priorities and brings sector experience in healthcare and life sciences, a global network and operational capabilities. The spokesperson said EQT has agreed to support Qiagen's long-term development, including commitments relating to strategy, business, key brands, operational footprint, R&D, employee arrangements, prudent financing and culture. The Qiagen boards concluded unanimously that private ownership under EQT offers the best foundation for the company's next phase of growth, combining operational flexibility with what they describe as certain and attractive value for shareholders.
Implementation of the post-closing measures will proceed if shareholder approval reaches at least 80% of votes cast. The boards retain discretion to proceed below that threshold if they determine it serves the best interests of the company and its stakeholders, provided there is support from a substantial majority of the shareholder base. Closing of the takeover offer is currently expected in mid-2027.
The transaction revives private interest in Qiagen after Thermo Fisher Scientific announced in March 2020 that it would acquire the company for $11.5 billion; that deal lapsed in August 2020.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.